MicroRNA signatures of colonic polyps on screening and histology

Cancer Prevention Research

Volumn 9, Issue 12, 2016, Pages 942-949

  Tsikitis, Vassiliki L ^a   Potter, Amiee ^b   Mori, Motomi ^b   Buckmeier, Julie A ^c   Preece, Christina R ^c   Harrington, Christina A ^b   Bartley, Angela N ^d   Bhattacharyya, Achyut K ^e   Hamilton, Stanley R ^d   Lance, M Peter ^e   Thompson, Patricia A ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d Integrated Healthcare Association   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 107; MICRORNA 107A; MICRORNA 124; MICRORNA 125B; MICRORNA 1268; MICRORNA 1275; MICRORNA 143; MICRORNA 145; MICRORNA 194; MICRORNA 199A; MICRORNA 214; MICRORNA 222; MICRORNA 26A; MICRORNA 30A; MICRORNA 320A; MICRORNA 320B; MICRORNA 335; MICRORNA 619; MICRORNA 663; MICRORNA 663B; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; COLON ADENOMA; COLON BIOPSY; COLON MUCOSA; COLON POLYP; COLON POLYPOSIS; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GASTROINTESTINAL DYSPLASIA; GENE EXPRESSION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPLASIA; HYPERPLASTIC POLYP; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECTUM ADENOMA; RNA ANALYSIS; SERRATED POLYP SESSILE SERRATED ADENOMA; TRADITIONAL SERRATED ADENOMA; TUBULOVILLOUS COLON ADENOMA; UPREGULATION; ADENOMA; CANCER GRADING; COLORECTAL TUMOR; EARLY CANCER DIAGNOSIS; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; PATHOLOGY; PROCEDURES; RISK; STATISTICAL MODEL;

ADENOMA; AGED; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LOGISTIC MODELS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; RISK;

EID: 85008323066     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-16-0086     Document Type: Article

References (43)

1. Lochhead P, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, et al. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol 2014;109: 1205-14.
2. Kulda V, Pesta M, Topolcan O, Liska V, Treska V, Sutnar A, et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet 2010;200:154-60.
3. Rossi S, Kopetz S, Davuluri R, Hamilton SR, Calin GA. MicroRNAs, ultraconserved genes and colorectal cancers. Int J Biochem Cell Biol 2010; 42:1291-7.
4. Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer 2012;130:2077-87.
5. Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JAF, Bolijn A, et al. Regulation of the adenomatous polyposis coliGene by the miR-135 family in colorectal cancer. Cancer Res 2008;68:5795-802.
6. Schetter AJ, Leung S, Sohn JJ, et al. MIcrorna expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-36.
7. Balaguer F, Link A, Lozano JJ, Cuatrecasas M, Nagasaka T, Boland CR, et al. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res 2010;70:6609-18.
8. Bartley AN, YaoH, Barkoh BA, Ivan C, Mishra BM, Rashid A, et al. Complex patterns of altered microRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer. Clin Cancer Res 2011;17:7283-93.
9. Oberg AL, French AJ, Sarver AL, Subramanian S, Morlan BW, Riska SM, et al. miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS ONE 2011;6:e20465.
10. Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, et al. DIANA-TarBase v7. 0: indexing more than half amillion experimentally supported miRNA:mRNA interactions. Nucleic Acids Res 2015;43:D153-9.
11. Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K, et al. Role of antioncomirs miR-143 and-145 in human colorectal tumors. Cancer Gene Ther 2010;17:398-408.
12. Miyaki M, Seki M, Okamoto M, Yamanaka A, Maeda Y, Tanaka K, et al. Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis. Cancer Res 1990;50: 7166-73.
13. Alberts DS, Martinez ME, Roe DJ, Guillen-Rodriguez JM, Marshall JR, van Leeuwen JB, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix colon cancer prevention physicians' network. N Engl J Med 2000;342:1156-62.
14. Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005;97:846-53.
15. Torlakovic E, Skovlund E, Snover DC, Torlakovic G, Nesland JM. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Path 2003;27:65-81.
16. Winawer SJ. Long-term follow-up after removal of colorectal adenomas provides evidence for risk stratification of patients at colonoscopic polypectomy. Evid Based Med 2015;20:29.
17. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US multi-society task force on colorectal cancer. Gastroenterology 2012;143:844-57.
18. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B (Methodological) 1995:57;289-300.
20. Klecka WR. Discriminant analysis: Sage; 1980.
21. Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene 2006;25:6170-5.
22. Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, et al. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 2012;130:2044-53.
23. Liu K, Guo L, Guo Y, Zhou B, Li T, Yang H, et al. AEG-1 3'-untranslated region functions as a ceRNAin inducing epithelial-mesenchymal transition of human non-small cell lung cancer by regulatingmiR-30a activity. Euro J Cell Biol 2015;94:22-31.
24. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010;138:2088-100.
25. Arain MA, Sawhney M, Sheikh S, Anway R, Thyagarajan B, Bond JH, et al. CIMP status of interval colon cancers: another piece to the puzzle. Am J Gastroenterol 2010;105:1189-95.
26. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, et al. BRAF mutation is associated withDNAmethylation in serrated polyps and cancers of the colorectum. Gut 2004;53:1137-44.
27. Spring KJ, Zhao ZZ, Karamatic R, Walsh MD, Whitehall VL, Pike T, et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006;131:1400-7.
28. Szylberg L, Janiczek M, Popiel A, Marszalek A. Serrated polyps and their alternative pathway to the colorectal cancer: a systematic review. Gastroenterol Res Pract 2015;2015:573814.
29. Sugumar A, Sinicrope FA. Serrated polyps of the colon. F1000 Med Reports 2010;2:89.
30. Dong SM, Lee EJ, Jeon ES, Park CK, Kim KM. Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Path 2005; 18:170-8.
31. Kamatani A, Nakagawa Y, Akao Y, Maruyama N, Nagasaka M, Shibata T, et al. Downregulation of anti-oncomirs miR-143/145 cluster occurs before APC gene aberration in the development of colorectal tumors. Med Mol Morphol 2013;46:166-71.
32. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011;71:225-33.
33. Wang B, Shen ZL, Gao ZD, Zhao G, Wang CY, Yang Y, et al. MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway. Cell Cycle 2015;14:1046-58.
34. Wang ZH, Ren LL, Zheng P, Zheng HM, Yu YN, Wang JL, et al. miR-194 as a predictor for adenoma recurrence in patients with advanced colorectal adenoma after polypectomy. Cancer Prev Res 2014;7:607-16.
35. Datta J, Smith A, Lang JC, Islam M, Dutt D, Teknos TN, et al. microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cvarepsilon. Oncogene 2012;31:4045-53.
36. Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 2012;18:1506-12.
37. Tome M, Lopez-Romero P, Albo C, Sepulveda JC, Fernandez-Gutierrez B, Dopazo A, et al. miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ 2011;18:985-95.
38. Najdi R, Holcombe RF, Waterman ML. Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog 2011;10:5.
39. Xia H, Ooi LL, Hui KM. MiR-214 targets beta-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PloS one. 2012;7:e44206.
40. Bar-Eli M. Searching for the melano-miRs': miR-214 drives melanoma metastasis. EMBO J 2011;30:1880-1.
41. Qiang R, Wang F, Shi LY, Liu M, Chen S, Wan HY, et al. Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Bioche Cell Biol 2011;43:632-41.
42. Chaudhuri AA, So AY, Sinha N, Gibson WS, Taganov KD, O'Connell RM, et al. MicroRNA-125b potentiates macrophage activation. J Immunol 2011;187:5062-8.
43. Pan Q, Bao LW, Teknos TN, Merajver SD. Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. Cancer Res 2006;66:9379-84.